Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer
Objectives: The objective of this study was to evaluate patterns of care and the survival impact of primary radiation and preoperative radiation therapy with surgery in women with locally advanced vulvar cancer using a large national cohort. Methods and Materials: Women with vulvar cancer, diagnosed...
Gespeichert in:
Veröffentlicht in: | International journal of gynecological cancer 2017-05, Vol.27 (4), p.794-804 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 804 |
---|---|
container_issue | 4 |
container_start_page | 794 |
container_title | International journal of gynecological cancer |
container_volume | 27 |
creator | Natesan, Divya Hong, Julian C. Foote, Jonathan Sosa, Julie A. Havrilesky, Laura Chino, Junzo |
description | Objectives: The objective of this study was to evaluate patterns of care and the survival impact of primary radiation and preoperative radiation therapy with surgery in women with locally advanced vulvar cancer using a large national cohort.
Methods and Materials: Women with vulvar cancer, diagnosed from 2004 to 2012, who received primary or preoperative radiation therapy were identified in the National Cancer Database. Patient characteristics, such as age, race, American Joint Committee on Cancer stage, and comorbidity score, were compared between those that received primary radiation only and those that received preoperative radiation with surgery using the χ2, Fisher exact, and Mann-Whitney tests as appropriate. Overall survival (OS) by treatment approaches was estimated via the Kaplan-Meier method and compared using the log-rank test. Factors associated with OS were determined using univariate and multivariate Cox proportional hazards regression models.
Results: A total of 2046 women were identified; 1407 of these women (69%) received primary radiation therapy (RT; n = 421) or chemoradiation therapy (CRT; n = 986) (RT/CRT), and 639 women (31%) received preoperative RT (n = 92) or CRT (n = 547) followed by surgery (RT/CRT + S). The American Joint Committee on Cancer staging distributions were as follows: T1 (n = 152), T2 (n = 1436), T3 (n = 405), N0 (n = 899), N1 (n = 480), N2 (n = 445), and N3 (n = 40). Median follow-up was 21.9 months. Primary RT/CRT was associated with compromised OS, compared with preoperative RT/CRT + S (41.7% vs 57.1% at 3 years, respectively; P < 0.001). On multivariate analysis, OS associated with primary RT/CRT with doses more than 55 Gy was not significantly different from RT/CRT + S (hazards ratio, 1.139; 95% confidence interval, 0.969-1.338; P = 0.116). Use of concurrent chemotherapy improved OS of primary RT with doses more than 55 Gy compared with CRT + S (hazards ratio, 1.107; 95% confidence interval, 0.919-1.334; P = 0.234).
Conclusions: In a large nationwide analysis, primary nonsurgical management of vulvar cancer with RT was associated with compromised survival compared with preoperative RT with surgery. However, with doses more than 55 Gy and concurrent chemotherapy, nonoperative approaches had comparable survival compared with preoperative CRT + S. |
doi_str_mv | 10.1097/IGC.0000000000000938 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881261867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1048891X24056962</els_id><sourcerecordid>1881261867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4398-a4b5dd198a238844af31c121d71a0dddf96ef4e9f1e0811d8cf75a10ede68baa3</originalsourceid><addsrcrecordid>eNqFkE1LJDEQhsOiqOv6D5alwcteWlOd9HTlIsiwfsCAIq54C5mkGtvNTMake8R_b4Z2ZfGw1qUq8Lwv4WHsO_Aj4Ko5vjyfHvF_Rwn8wvagruoSpMCtfHOJJSq432VfU3rcMBVXO2y3QiEESr7HLq5jtzDxpbijmIZUXEcKK4qm79ZU3BjX5SssizbEYhas8f6lOHVrs7TkirvBr00spptX_Ma2W-MTHbztffb77Nft9KKcXZ1fTk9npZVCYWnkvHYOFJpKIEppWgEWKnANGO6ca9WEWkmqBeII4NC2TW2Ak6MJzo0R--zn2LuK4Wmg1OtFlyx5b5YUhqQBEaoJ4KTJ6OEH9DEMcZl_p6u6URyF4lWm5EjZGFKK1OrVqEQD1xvTOpvWH03n2I-38mG-IPce-qs2AzgCz8H3We4fPzxT1A9kfP_wWffJGKUsct3lVLIdbZx3kWyvXej-X_AKg56c1Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579083902</pqid></control><display><type>article</type><title>Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Natesan, Divya ; Hong, Julian C. ; Foote, Jonathan ; Sosa, Julie A. ; Havrilesky, Laura ; Chino, Junzo</creator><creatorcontrib>Natesan, Divya ; Hong, Julian C. ; Foote, Jonathan ; Sosa, Julie A. ; Havrilesky, Laura ; Chino, Junzo</creatorcontrib><description>Objectives: The objective of this study was to evaluate patterns of care and the survival impact of primary radiation and preoperative radiation therapy with surgery in women with locally advanced vulvar cancer using a large national cohort.
Methods and Materials: Women with vulvar cancer, diagnosed from 2004 to 2012, who received primary or preoperative radiation therapy were identified in the National Cancer Database. Patient characteristics, such as age, race, American Joint Committee on Cancer stage, and comorbidity score, were compared between those that received primary radiation only and those that received preoperative radiation with surgery using the χ2, Fisher exact, and Mann-Whitney tests as appropriate. Overall survival (OS) by treatment approaches was estimated via the Kaplan-Meier method and compared using the log-rank test. Factors associated with OS were determined using univariate and multivariate Cox proportional hazards regression models.
Results: A total of 2046 women were identified; 1407 of these women (69%) received primary radiation therapy (RT; n = 421) or chemoradiation therapy (CRT; n = 986) (RT/CRT), and 639 women (31%) received preoperative RT (n = 92) or CRT (n = 547) followed by surgery (RT/CRT + S). The American Joint Committee on Cancer staging distributions were as follows: T1 (n = 152), T2 (n = 1436), T3 (n = 405), N0 (n = 899), N1 (n = 480), N2 (n = 445), and N3 (n = 40). Median follow-up was 21.9 months. Primary RT/CRT was associated with compromised OS, compared with preoperative RT/CRT + S (41.7% vs 57.1% at 3 years, respectively; P < 0.001). On multivariate analysis, OS associated with primary RT/CRT with doses more than 55 Gy was not significantly different from RT/CRT + S (hazards ratio, 1.139; 95% confidence interval, 0.969-1.338; P = 0.116). Use of concurrent chemotherapy improved OS of primary RT with doses more than 55 Gy compared with CRT + S (hazards ratio, 1.107; 95% confidence interval, 0.919-1.334; P = 0.234).
Conclusions: In a large nationwide analysis, primary nonsurgical management of vulvar cancer with RT was associated with compromised survival compared with preoperative RT with surgery. However, with doses more than 55 Gy and concurrent chemotherapy, nonoperative approaches had comparable survival compared with preoperative CRT + S.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1097/IGC.0000000000000938</identifier><identifier>PMID: 28333840</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Cancer therapies ; Chemoradiation ; Chemoradiotherapy - statistics & numerical data ; Chemotherapy ; Cohort Studies ; Confidence intervals ; Databases, Factual ; Definitive therapy ; Female ; Genital cancers ; Humans ; Middle Aged ; NCDB ; Neoadjuvant Therapy - statistics & numerical data ; Proportional Hazards Models ; Radiation therapy ; Radiotherapy, Adjuvant - statistics & numerical data ; Retrospective Studies ; Surgery ; Survival Rate ; Treatment Outcome ; United States - epidemiology ; Vulvar cancer ; Vulvar Neoplasms - drug therapy ; Vulvar Neoplasms - mortality ; Vulvar Neoplasms - radiotherapy ; Vulvar Neoplasms - surgery</subject><ispartof>International journal of gynecological cancer, 2017-05, Vol.27 (4), p.794-804</ispartof><rights>2017 IGCS and ESGO</rights><rights>2017 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.</rights><rights>2017 2017 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4398-a4b5dd198a238844af31c121d71a0dddf96ef4e9f1e0811d8cf75a10ede68baa3</citedby><cites>FETCH-LOGICAL-c4398-a4b5dd198a238844af31c121d71a0dddf96ef4e9f1e0811d8cf75a10ede68baa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28333840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Natesan, Divya</creatorcontrib><creatorcontrib>Hong, Julian C.</creatorcontrib><creatorcontrib>Foote, Jonathan</creatorcontrib><creatorcontrib>Sosa, Julie A.</creatorcontrib><creatorcontrib>Havrilesky, Laura</creatorcontrib><creatorcontrib>Chino, Junzo</creatorcontrib><title>Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>Objectives: The objective of this study was to evaluate patterns of care and the survival impact of primary radiation and preoperative radiation therapy with surgery in women with locally advanced vulvar cancer using a large national cohort.
Methods and Materials: Women with vulvar cancer, diagnosed from 2004 to 2012, who received primary or preoperative radiation therapy were identified in the National Cancer Database. Patient characteristics, such as age, race, American Joint Committee on Cancer stage, and comorbidity score, were compared between those that received primary radiation only and those that received preoperative radiation with surgery using the χ2, Fisher exact, and Mann-Whitney tests as appropriate. Overall survival (OS) by treatment approaches was estimated via the Kaplan-Meier method and compared using the log-rank test. Factors associated with OS were determined using univariate and multivariate Cox proportional hazards regression models.
Results: A total of 2046 women were identified; 1407 of these women (69%) received primary radiation therapy (RT; n = 421) or chemoradiation therapy (CRT; n = 986) (RT/CRT), and 639 women (31%) received preoperative RT (n = 92) or CRT (n = 547) followed by surgery (RT/CRT + S). The American Joint Committee on Cancer staging distributions were as follows: T1 (n = 152), T2 (n = 1436), T3 (n = 405), N0 (n = 899), N1 (n = 480), N2 (n = 445), and N3 (n = 40). Median follow-up was 21.9 months. Primary RT/CRT was associated with compromised OS, compared with preoperative RT/CRT + S (41.7% vs 57.1% at 3 years, respectively; P < 0.001). On multivariate analysis, OS associated with primary RT/CRT with doses more than 55 Gy was not significantly different from RT/CRT + S (hazards ratio, 1.139; 95% confidence interval, 0.969-1.338; P = 0.116). Use of concurrent chemotherapy improved OS of primary RT with doses more than 55 Gy compared with CRT + S (hazards ratio, 1.107; 95% confidence interval, 0.919-1.334; P = 0.234).
Conclusions: In a large nationwide analysis, primary nonsurgical management of vulvar cancer with RT was associated with compromised survival compared with preoperative RT with surgery. However, with doses more than 55 Gy and concurrent chemotherapy, nonoperative approaches had comparable survival compared with preoperative CRT + S.</description><subject>Aged</subject><subject>Cancer therapies</subject><subject>Chemoradiation</subject><subject>Chemoradiotherapy - statistics & numerical data</subject><subject>Chemotherapy</subject><subject>Cohort Studies</subject><subject>Confidence intervals</subject><subject>Databases, Factual</subject><subject>Definitive therapy</subject><subject>Female</subject><subject>Genital cancers</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>NCDB</subject><subject>Neoadjuvant Therapy - statistics & numerical data</subject><subject>Proportional Hazards Models</subject><subject>Radiation therapy</subject><subject>Radiotherapy, Adjuvant - statistics & numerical data</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>United States - epidemiology</subject><subject>Vulvar cancer</subject><subject>Vulvar Neoplasms - drug therapy</subject><subject>Vulvar Neoplasms - mortality</subject><subject>Vulvar Neoplasms - radiotherapy</subject><subject>Vulvar Neoplasms - surgery</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkE1LJDEQhsOiqOv6D5alwcteWlOd9HTlIsiwfsCAIq54C5mkGtvNTMake8R_b4Z2ZfGw1qUq8Lwv4WHsO_Aj4Ko5vjyfHvF_Rwn8wvagruoSpMCtfHOJJSq432VfU3rcMBVXO2y3QiEESr7HLq5jtzDxpbijmIZUXEcKK4qm79ZU3BjX5SssizbEYhas8f6lOHVrs7TkirvBr00spptX_Ma2W-MTHbztffb77Nft9KKcXZ1fTk9npZVCYWnkvHYOFJpKIEppWgEWKnANGO6ca9WEWkmqBeII4NC2TW2Ak6MJzo0R--zn2LuK4Wmg1OtFlyx5b5YUhqQBEaoJ4KTJ6OEH9DEMcZl_p6u6URyF4lWm5EjZGFKK1OrVqEQD1xvTOpvWH03n2I-38mG-IPce-qs2AzgCz8H3We4fPzxT1A9kfP_wWffJGKUsct3lVLIdbZx3kWyvXej-X_AKg56c1Q</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Natesan, Divya</creator><creator>Hong, Julian C.</creator><creator>Foote, Jonathan</creator><creator>Sosa, Julie A.</creator><creator>Havrilesky, Laura</creator><creator>Chino, Junzo</creator><general>Elsevier Inc</general><general>by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer</title><author>Natesan, Divya ; Hong, Julian C. ; Foote, Jonathan ; Sosa, Julie A. ; Havrilesky, Laura ; Chino, Junzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4398-a4b5dd198a238844af31c121d71a0dddf96ef4e9f1e0811d8cf75a10ede68baa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Cancer therapies</topic><topic>Chemoradiation</topic><topic>Chemoradiotherapy - statistics & numerical data</topic><topic>Chemotherapy</topic><topic>Cohort Studies</topic><topic>Confidence intervals</topic><topic>Databases, Factual</topic><topic>Definitive therapy</topic><topic>Female</topic><topic>Genital cancers</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>NCDB</topic><topic>Neoadjuvant Therapy - statistics & numerical data</topic><topic>Proportional Hazards Models</topic><topic>Radiation therapy</topic><topic>Radiotherapy, Adjuvant - statistics & numerical data</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>United States - epidemiology</topic><topic>Vulvar cancer</topic><topic>Vulvar Neoplasms - drug therapy</topic><topic>Vulvar Neoplasms - mortality</topic><topic>Vulvar Neoplasms - radiotherapy</topic><topic>Vulvar Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Natesan, Divya</creatorcontrib><creatorcontrib>Hong, Julian C.</creatorcontrib><creatorcontrib>Foote, Jonathan</creatorcontrib><creatorcontrib>Sosa, Julie A.</creatorcontrib><creatorcontrib>Havrilesky, Laura</creatorcontrib><creatorcontrib>Chino, Junzo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Natesan, Divya</au><au>Hong, Julian C.</au><au>Foote, Jonathan</au><au>Sosa, Julie A.</au><au>Havrilesky, Laura</au><au>Chino, Junzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>27</volume><issue>4</issue><spage>794</spage><epage>804</epage><pages>794-804</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>Objectives: The objective of this study was to evaluate patterns of care and the survival impact of primary radiation and preoperative radiation therapy with surgery in women with locally advanced vulvar cancer using a large national cohort.
Methods and Materials: Women with vulvar cancer, diagnosed from 2004 to 2012, who received primary or preoperative radiation therapy were identified in the National Cancer Database. Patient characteristics, such as age, race, American Joint Committee on Cancer stage, and comorbidity score, were compared between those that received primary radiation only and those that received preoperative radiation with surgery using the χ2, Fisher exact, and Mann-Whitney tests as appropriate. Overall survival (OS) by treatment approaches was estimated via the Kaplan-Meier method and compared using the log-rank test. Factors associated with OS were determined using univariate and multivariate Cox proportional hazards regression models.
Results: A total of 2046 women were identified; 1407 of these women (69%) received primary radiation therapy (RT; n = 421) or chemoradiation therapy (CRT; n = 986) (RT/CRT), and 639 women (31%) received preoperative RT (n = 92) or CRT (n = 547) followed by surgery (RT/CRT + S). The American Joint Committee on Cancer staging distributions were as follows: T1 (n = 152), T2 (n = 1436), T3 (n = 405), N0 (n = 899), N1 (n = 480), N2 (n = 445), and N3 (n = 40). Median follow-up was 21.9 months. Primary RT/CRT was associated with compromised OS, compared with preoperative RT/CRT + S (41.7% vs 57.1% at 3 years, respectively; P < 0.001). On multivariate analysis, OS associated with primary RT/CRT with doses more than 55 Gy was not significantly different from RT/CRT + S (hazards ratio, 1.139; 95% confidence interval, 0.969-1.338; P = 0.116). Use of concurrent chemotherapy improved OS of primary RT with doses more than 55 Gy compared with CRT + S (hazards ratio, 1.107; 95% confidence interval, 0.919-1.334; P = 0.234).
Conclusions: In a large nationwide analysis, primary nonsurgical management of vulvar cancer with RT was associated with compromised survival compared with preoperative RT with surgery. However, with doses more than 55 Gy and concurrent chemotherapy, nonoperative approaches had comparable survival compared with preoperative CRT + S.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28333840</pmid><doi>10.1097/IGC.0000000000000938</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1048-891X |
ispartof | International journal of gynecological cancer, 2017-05, Vol.27 (4), p.794-804 |
issn | 1048-891X 1525-1438 |
language | eng |
recordid | cdi_proquest_miscellaneous_1881261867 |
source | MEDLINE; Journals@Ovid Ovid Autoload |
subjects | Aged Cancer therapies Chemoradiation Chemoradiotherapy - statistics & numerical data Chemotherapy Cohort Studies Confidence intervals Databases, Factual Definitive therapy Female Genital cancers Humans Middle Aged NCDB Neoadjuvant Therapy - statistics & numerical data Proportional Hazards Models Radiation therapy Radiotherapy, Adjuvant - statistics & numerical data Retrospective Studies Surgery Survival Rate Treatment Outcome United States - epidemiology Vulvar cancer Vulvar Neoplasms - drug therapy Vulvar Neoplasms - mortality Vulvar Neoplasms - radiotherapy Vulvar Neoplasms - surgery |
title | Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T15%3A40%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20Versus%20Preoperative%20Radiation%20for%20Locally%20Advanced%20Vulvar%20Cancer&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Natesan,%20Divya&rft.date=2017-05-01&rft.volume=27&rft.issue=4&rft.spage=794&rft.epage=804&rft.pages=794-804&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1097/IGC.0000000000000938&rft_dat=%3Cproquest_cross%3E1881261867%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579083902&rft_id=info:pmid/28333840&rft_els_id=S1048891X24056962&rfr_iscdi=true |